BIOGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 215.5 USD | +3.16% |
|
+11.02% | -16.72% |
| Apr. 29 | Wall Street: buoyed by Tesla, confident ahead of FOMC meeting | CF |
| Apr. 26 | Guggenheim Adjusts Price Target on Biogen to $255 From $275 | MT |
ETFs positioned on Biogen Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 2 M€ | +3.16% | - | |
| 0.04% | 186 M€ | -1.58% | - | |
| 0.03% | 1 M€ | +3.03% | - | |
| 0.03% | 15 M€ | -1.62% | - | |
| 0.03% | 108 M€ | +2.34% | - | |
| 0.03% | 7 M€ | +0.11% | - | |
| 0.03% | 6 M€ | +3.89% | ||
| 0.02% | 17 M€ | +1.44% | - | |
| 0.02% | 147 M€ | +4.88% | - | |
| 0.02% | 12 M€ | +9.34% | - | |
| 0.01% | 52 M€ | -0.13% | - | |
| 0.01% | 8 M€ | -0.60% | - | |
| 0.01% | 237 M€ | +3.51% | - | |
| 0.01% | 6 M€ | -4.26% | - | |
| 0.01% | 117 M€ | +1.54% | - | |
| 0.00% | 34 M€ | +2.43% | - | |
| 3.88% | 121 M€ | +4.54% | - | |
| 4.33% | 36 M€ | +3.01% | - |
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
215.5
USD
Average target price
286
USD
Spread / Average Target
+32.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.72% | 30.42B | |
| -3.81% | 86.13B | |
| +1.97% | 39.82B | |
| +56.59% | 25.23B | |
| -14.82% | 15.36B | |
| -8.82% | 11.95B | |
| -16.29% | 11.6B | |
| -41.58% | 11.51B | |
| +6.14% | 8.71B | |
| -7.84% | 8.12B |
- Stock Market
- Equities
- BIIB Stock
- Funds and ETFs Biogen Inc.
